Is Eli Lilly (LLY) Trading At A Discount To Future Cash Flow?

Eli Lilly has turned into one of the most closely watched stocks in global healthcare, and with that attention comes a simple question for investors. At around US$1,152.93 per share, is the current price in line with the cash flows that Lilly can plausibly generate over time?

• Over the past 5 years, Eli Lilly has delivered a very large total return of about 4.2x, which puts a lot of weight on whether its cash flows can keep supporting such a re-rating.
• Recent approvals and upgrades around oncology and obesity treatments may support expectations for stronger and more durable cash generation. This feeds directly into how a Discounted Cash Flow (DCF) estimate is built for Eli Lilly.
• What if you looked at Eli Lilly through its earnings instead? See what Eli Lilly's 38.5x P/E says about the price.

For investors, the debate is whether Eli Lilly's share price around US$1,152.93 is adequately supported by the cash flows implied in a Discounted Cash Flow (DCF) intrinsic value estimate.

For anyone weighing Eli Lilly after this run, a focused stock screen built around similar quality hurdles can be a useful second starting point for research, especially with tools like 33 high quality undervalued stocks.

Does Eli Lilly Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model here is built on Eli Lilly's ability to convert its drug portfolio into future free cash available to shareholders. Over the last twelve months, Lilly produced about $13.6b of free cash flow, and the model assumes that this figure grows over time rather than shrinking. Those projections step up meaningfully into the early 2030s, which is a key reason the DCF output points to an estimated intrinsic value that sits substantially above the current share price of US$1,152.93.

The recent full U.S. FDA approval of Inluriyo in combination with Verzenio for certain advanced breast cancer patients illustrates why the forecasts lean toward expanding cash generation, because it adds another targeted therapy to Eli Lilly's oncology franchise. Despite that pipeline support and the DCF suggesting value above where the equity now trades, the market price still reflects its own view of the risk around execution, regulation, and future competition. Find out what Eli Lilly could be worth using our Discounted Cash Flow (DCF) estimate.

The Eli Lilly Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Eli Lilly pick up where the DCF puzzle leaves off and spell out which assumptions on growth, profitability and earnings would need to hold for the stock to be worth materially more or less than today’s price, all housed on the Community page. Each narrative treats Eli Lilly's implied valuation as a thesis about the business that can be tracked over time rather than a one off snapshot.

Community views on Eli Lilly split between investors who think the current price roughly matches the fundamentals and those who see it about 17% overvalued.

Bull case: roughly fairly valued

"Market penetration for all GLP-1 drugs is only at 4% of target audience of 100 to 120 Million people in the USA alone…"

Discover why this Narrative puts Eli Lilly at roughly fairly valued.

Bear case: 17% overvalued

"Heavily concentrated revenue in a narrow set of leading drugs, including Mounjaro, Zepbound, and Trulicity, makes Lilly especially vulnerable…"

Explore why this Narrative puts Eli Lilly at 17% overvalued.

One more Eli Lilly check that belongs beside the price tag

Eli Lilly’s valuation story is only part of what matters, because recent research has also surfaced specific risk checks that investors may want to weigh before going further. Take a closer look at 1 warning sign before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com